Diabetic foot ulcers (DFUs) represent a significant complication of diabetes mellitus, affecting 12-25% of individuals with the condition over their lifetime. These ulcers, often resulting from neuropathy, peripheral arterial disease (PAD), or a combination thereof, predominantly occur on the plantar surface or margins of the foot. Without proper management, DFUs can lead to severe outcomes, including infections, gangrene, and lower limb amputations, which precede 84% of such procedures. Central to DFU treatment is offloading—reducing pressure and shear forces on the ulcerated area to promote healing. Among offloading modalities, the Total Contact Cast (TCC) stands out as the gold standard, particularly for neuropathic plantar ulcers, as endorsed by international guidelines like those from the International Working Group on the Diabetic Foot (IWGDF). This essay explores the use of TCC in DFU management, covering its mechanism, application, benefits, risks, barriers, and comparisons to alternatives.
TCC is a specialized casting technique designed to heal DFUs by evenly distributing weight across the entire sole of the foot while protecting it during vulnerable phases, such as early Charcot fracture dislocations. Unlike standard casts, TCC maintains close contact with the foot’s contours, from the heel through the arch, metatarsals, and toes. This rigid or semi-rigid cast extends from the foot to just below the knee, incorporating minimal padding to safeguard bony prominences. The concept of TCC dates back to the mid-20th century but gained prominence in diabetic care through studies in the 1980s and 1990s, evolving with materials like fiberglass for lighter, more durable versions. Modern variants, such as TCC-EZ, simplify application, reducing time from hours to about 21 minutes.
The mechanism of TCC revolves around pressure redistribution and forced compliance. By molding precisely to the foot, it reduces peak plantar pressures by 30-36% compared to cast shoes and minimizes shear forces through firm positioning. This offloading prevents further tissue breakdown, allowing epithelialization and granulation. Additionally, TCC limits patient activity, shortens stride length, and decreases vertical forces, all contributing to ulcer healing. In contrast to removable devices, which patients wear only 28% of the time, TCC ensures continuous offloading, as it cannot be easily removed. For visualization, here are examples of TCC application:
The application process requires expertise to avoid complications. Patients typically lie prone with the leg elevated and ankle in neutral position. A thin dressing covers the ulcer, followed by stockinette and protective padding over toes, ankles, and shin. Plaster forms the undercoat, molded to fill sole valleys for a flat walking surface, often reinforced with fiberglass. A rocker-bottom sole aids gait. Casts are changed weekly or bi-weekly to monitor healing and adjust for swelling, continuing until the ulcer resolves and the foot transitions to orthotics or boots. In Charcot cases, initial non-weight-bearing may be enforced.
Benefits of TCC are well-documented, with healing rates of 89-92% for neuropathic plantar DFUs, surpassing general offloading (60-77%). Studies like Nabuurs-Franssen et al. (2005) reported 90% healing for diabetic peripheral neuropathy (DPN) alone, 87% for DPN with infection, 69% for DPN with PAD, but only 36% for the triad of DPN, PAD, and infection. Armstrong et al. (2001) demonstrated faster healing with TCC versus other devices, while Lavery et al. (2015) showed superiority over healing sandals and removable boots. Cost-effectiveness is notable: $11,946 per patient versus $22,494 for alternatives. Even in complex cases with moderate PAD or infection, TCC improves outcomes when monitored closely. A recent 2024 study, though inaccessible in detail here, reaffirmed TCC’s efficacy, with most DFUs healing completely, particularly benefiting PAD patients alongside revascularization.
Despite advantages, risks exist. A retrospective review of 384 patients with 2,265 casts found 10% experiencing at least one complication using stringent criteria, including new ulcers, increased odor/drainage, infections, gangrene, osteomyelitis, or pain requiring cast changes. Iatrogenic ulceration occurs in about 5.52% of casts, though these often heal before the primary ulcer. Other issues include muscle atrophy, bone density loss (mitigated by fiberglass), and leg length discrepancies causing instability. Elevated Hemoglobin A1C correlates with higher risks. Contraindications include severe infections without expertise or high exudate, necessitating modifications like bi-valve casts. Side effects like sores under the cast are risks for diabetics, emphasizing the need for vascular assessment pre-application and frequent changes.
Barriers to TCC adoption include skill requirements, time consumption, and perceived risks, leading to underuse—45% of clinics offer no offloading, favoring ineffective footwear. Innovations like instant TCCs address this, showing equal efficacy. Compared to removable walkers (lower compliance) or shear-reducing devices, TCC yields higher healing rates, though meta-analyses confirm non-removable offloading’s edge. Patient education on cast monitoring and contralateral leg protection minimizes issues.
The TCC remains a cornerstone in DFU treatment, offering superior healing through effective offloading and compliance. While risks like complications (10%) and barriers like application complexity persist, evidence supports its use, especially in multidisciplinary settings. With DFUs costing $9-13 billion annually in the US, promoting TCC could reduce amputations and improve quality of life. Future research should focus on simplifying techniques to broaden access.